JP4422228B2 - 活性化血液凝固第ｖｉｉ因子に特異的なモノクローナル抗体およびその使用 - Google Patents

活性化血液凝固第ｖｉｉ因子に特異的なモノクローナル抗体およびその使用 Download PDF

Info

Publication number
JP4422228B2
JP4422228B2 JP01261099A JP1261099A JP4422228B2 JP 4422228 B2 JP4422228 B2 JP 4422228B2 JP 01261099 A JP01261099 A JP 01261099A JP 1261099 A JP1261099 A JP 1261099A JP 4422228 B2 JP4422228 B2 JP 4422228B2
Authority
JP
Japan
Prior art keywords
blood coagulation
factor vii
coagulation factor
activated blood
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP01261099A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11279199A5 (enExample
JPH11279199A (ja
Inventor
イュルゲン・レーミシュ
ヴィーガント・ラング
アネッテ・フォイスナー
ヨーアヒム・レーダー
Original Assignee
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー filed Critical ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Publication of JPH11279199A publication Critical patent/JPH11279199A/ja
Publication of JPH11279199A5 publication Critical patent/JPH11279199A5/ja
Application granted granted Critical
Publication of JP4422228B2 publication Critical patent/JP4422228B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP01261099A 1998-01-22 1999-01-21 活性化血液凝固第ｖｉｉ因子に特異的なモノクローナル抗体およびその使用 Expired - Fee Related JP4422228B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19802139:9 1998-01-22
DE19802139A DE19802139C1 (de) 1998-01-22 1998-01-22 Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung

Publications (3)

Publication Number Publication Date
JPH11279199A JPH11279199A (ja) 1999-10-12
JPH11279199A5 JPH11279199A5 (enExample) 2006-04-06
JP4422228B2 true JP4422228B2 (ja) 2010-02-24

Family

ID=7855234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP01261099A Expired - Fee Related JP4422228B2 (ja) 1998-01-22 1999-01-21 活性化血液凝固第ｖｉｉ因子に特異的なモノクローナル抗体およびその使用

Country Status (9)

Country Link
US (2) US6479245B1 (enExample)
EP (1) EP0931793B1 (enExample)
JP (1) JP4422228B2 (enExample)
KR (1) KR100583537B1 (enExample)
AT (1) ATE261991T1 (enExample)
AU (1) AU742631B2 (enExample)
CA (1) CA2259724C (enExample)
DE (2) DE19802139C1 (enExample)
ES (1) ES2217492T3 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
EP1356052B1 (en) * 2000-12-14 2008-08-20 Genentech, Inc. Production of full antibodies in procaryotic cells
AU2002327192B2 (en) * 2001-07-03 2007-02-15 Oklahoma Medical Research Foundation Assay for measuring factor VIIa-antithrombin complexes
PE20212262A1 (es) 2019-04-17 2021-11-29 Novo Nordisk As Anticuerpos biespecificos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung

Also Published As

Publication number Publication date
US6835817B2 (en) 2004-12-28
DE19802139C1 (de) 1999-09-23
EP0931793A1 (de) 1999-07-28
CA2259724A1 (en) 1999-07-22
AU742631B2 (en) 2002-01-10
ATE261991T1 (de) 2004-04-15
ES2217492T3 (es) 2004-11-01
US20030003096A1 (en) 2003-01-02
US6479245B1 (en) 2002-11-12
KR19990068047A (ko) 1999-08-25
AU1318599A (en) 1999-08-12
KR100583537B1 (ko) 2006-05-26
JPH11279199A (ja) 1999-10-12
EP0931793B1 (de) 2004-03-17
CA2259724C (en) 2010-07-13
DE59810998D1 (de) 2004-04-22

Similar Documents

Publication Publication Date Title
JP2669566B2 (ja) 遊離及び複合体形成した前立腺特異的抗原（ｐｓａ）の分析
CA2112702C (en) Assay methods and compositions for detecting serum proteases, particularly activated protein c
JPH0772200B2 (ja) 人フィブリンｉｉのｎｈ２ 末端フラグメントに対するモノクロナール抗体
CA2071211C (en) Immunoassays for and monoclonal antibodies to prothrombin activation peptides and their degradation products
AU690535B2 (en) Novel anticoagulant cofactor activity
CA2259724C (en) Monoclonal antibody which is specific for activated coagulation factor vii, and its use
JP4398648B2 (ja) 血液凝固第ｖｉｉ因子活性化プロテアーゼに対する抑制性モノクローナル抗体
AU2003295144A1 (en) Detection or determination of variants of factor XIIa
WO2001098782A1 (fr) Kit de determination du pouvoir de coagulation du sang
WO1993000364A1 (en) ASSAY FOR DETECTING FIBRINOLYSIS AND FIBRINOGENOLYSIS BASED ON COOH-TERMINAL Aα CHAIN MARKERS
JPH03200066A (ja) 活性化ヒトプロテインｃの測定方法
HU201844B (en) Immun adsorptive-amidolytic method for detecting plasminogen activator precursor (pro-uppa) and plasminogen activator (upa) of the human urine
JPH03187396A (ja) 抗体，抗体産生ハイブリドーマおよび抗体の用途
JPWO2001098782A1 (ja) 血液凝固能測定キット

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090721

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091110

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091204

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121211

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121211

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131211

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees